QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.103.049817v1 306/3/1021    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kandler, M. A. Articles by Dötsch, J. Search for Related Content PubMed PubMed Citation Articles by Kandler, M. A. Articles by Dötsch, J.

CARDIOVASCULAR

Pilot Intervention: Aerosolized Adrenomedullin Reduces Pulmonary Hypertension

Klinik für Kinder und Jugendliche (M.A.K., K.v.d.H., S.M., M.C., E.S., W.R., J.D.), Pathologisch-Anatomisches Institut (T.P.) der Friedrich-Alexander-Universität, Erlangen-Nuernberg, Germany

In pulmonary hypertension, systemic infusion of adrenomedullin (ADM), a potent vasodilator peptide, leads to pulmonary vasodilatation. However, systemic blood pressure declines alike. The present study investigated the effect of aerosolized ADM on pulmonary arterial pressure in surfactant-depleted newborn piglets with pulmonary hypertension. Animals randomly received aerosolized ADM (ADM, n = 6), aerosolized ADM combined with intravenous application of N^G-nitro-L-arginine methylester to inhibit nitric-oxide (NO) synthases (ADM + L-NAME, n = 5), or aerosolized normal saline solution (control, n = 6). Aerosol therapy was performed in 30-min intervals for 5 h. After a total experimental period of 8 h, mRNA expression of endothelial and inducible NO synthase and endothelin-1 (ET-1) in lung tissue was quantified using TaqMan real-time polymerase chain reaction. Aerosolized ADM reduced mean pulmonary artery pressure (MPAP) compared with control (p < 0.001; at the end of the study, -MPAP -13.5 ± 1.4 versus -6.2 ± 2.4 mm Hg). PaO₂ significantly increased in the ADM (PaO₂ 243.3 mm Hg) and the ADM + L-NAME group (PaO₂ 217.4 mm Hg) compared with the control group (PaO₂ 82.9 mm Hg; p < 0.001). Aerosolized ADM did not influence mean systemic arterial pressure (baseline 63.2 ± 2.7 versus end of the study 66.3 ± 6.5 mm Hg; not significant). NO synthases gene expressions were 20 to 30% lower with ADM compared with control. ET-1 gene expression was significantly reduced (>50%) after ADM aerosol therapy (p < 0.001). Aerosolized adrenomedullin significantly reduced MPAP without lowering the systemic arterial pressure and improved profoundly the arterial oxygen tension. This effect seems to be mediated at least in part by the reduction of ET-1.

Address correspondence to: Dr. M. A. Kandler, Universitätsklinik für Kinder und Jugendliche, Loschgestrasse 15, 91054 Erlangen/Germany. E-mail: michael.kandler{at}web.de

This article has been cited by other articles:

				T. Dschietzig, C. Richter, L. Asswad, G. Baumann, and K. Stangl Hypoxic Induction of Receptor Activity-Modifying Protein 2 Alters Regulation of Pulmonary Endothelin-1 by Adrenomedullin: Induction under Normoxia Versus Inhibition under Hypoxia J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 409 - 419. [Abstract] [Full Text] [PDF]

				T. M. Bull, C. D. Coldren, M. Moore, S. M. Sotto-Santiago, D. V. Pham, S. P. Nana-Sinkam, N. F. Voelkel, and M. W. Geraci Gene Microarray Analysis of Peripheral Blood Cells in Pulmonary Arterial Hypertension Am. J. Respir. Crit. Care Med., October 15, 2004; 170(8): 911 - 919. [Abstract] [Full Text] [PDF]

				M. Westphal, M. Booke, and A.T. Dinh-Xuan Adrenomedullin: a smart road from pheochromocytoma to treatment of pulmonary hypertension Eur. Respir. J., October 1, 2004; 24(4): 518 - 520. [Full Text] [PDF]

				K. von der Hardt, M.A. Kandler, M. Chada, A. Cubra, E. Schoof, K. Amann, W. Rascher, and J. Dotsch Brief adrenomedullin inhalation leads to sustained reduction of pulmonary artery pressure Eur. Respir. J., October 1, 2004; 24(4): 615 - 623. [Abstract] [Full Text] [PDF]